Mechanism of E2F1-induced Apoptosis in Primary Vascular Smooth Muscle Cells
Overview
Authors
Affiliations
Objective: The transcription factor E2F1 serves as a major regulator of the cell-cycle by controlling G1-S phase transition. However, apart from its proliferative function high levels of deregulated E2F1 are capable of inducing apoptosis depending on the cellular context. In particular the tumor suppressor p53 and its homologue p73 are implicated in this proapoptotic function.
Methods: Here, we investigated the mechanistic basis for E2F1-mediated apoptosis in vascular smooth muscle cells (VSMCs) which have previously been shown to be E2F1-responsive.
Results: Interestingly, E2F1-expression in these cells induced clear signs of apoptosis in the absence of any proliferative activity. Although cell-cycle regulated genes such as CCNE1 and CDC25A were activated, BrdU-staining revealed no S-phase entry. Instead, a rapid loss of cell viability by induction of apoptosis was observed. Using a transactivation-defective E2F1-mutant, we show that apoptosis induction is independent of the transactivation function and therefore independent of ARF and p73. However, this mutant retains its ability to stabilize and phosphorylate p53, suggesting that p53 is sufficient for the effect of E2F1.
Conclusion: VSMCs therefore represent a cellular system in which the transactivation-independent, proapoptotic activity of E2F1 is the primary cellular function. Ectopic expression of E2F1 might therefore be a suitable therapy to prevent VSMC hyperproliferation.
Son D, Jung J, Hong J PLoS One. 2016; 11(5):e0155859.
PMID: 27218463 PMC: 4878802. DOI: 10.1371/journal.pone.0155859.
Liu D, Pattabiraman V, Bacanamwo M, Anderson L Am J Physiol Cell Physiol. 2016; 311(2):C179-89.
PMID: 27170637 PMC: 5129766. DOI: 10.1152/ajpcell.00293.2015.
Transcriptional repression of the prosurvival endoplasmic reticulum chaperone GRP78/BIP by E2F1.
Racek T, Buhlmann S, Rust F, Knoll S, Alla V, Putzer B J Biol Chem. 2008; 283(49):34305-14.
PMID: 18840615 PMC: 2662239. DOI: 10.1074/jbc.M803925200.
Li Z, Putzer B J Cell Mol Med. 2008; 12(6A):2427-38.
PMID: 18208561 PMC: 4514120. DOI: 10.1111/j.1582-4934.2008.00244.x.
E2F1 death pathways as targets for cancer therapy.
Putzer B J Cell Mol Med. 2007; 11(2):239-51.
PMID: 17488475 PMC: 3822825. DOI: 10.1111/j.1582-4934.2007.00030.x.